

# Louis B Nabors

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/443248/publications.pdf>

Version: 2024-02-01

171  
papers

11,924  
citations

28274

55  
h-index

28297

105  
g-index

175  
all docs

175  
docs citations

175  
times ranked

14231  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>SRI</scp>â€42127, a novel small molecule inhibitor of the <scp>RNA</scp> regulator <scp>HuR</scp>, potently attenuates glial activation in a model of lipopolysaccharideâ€induced neuroinflammation. <i>Glia</i> , 2022, 70, 155-172.	4.9	10
2	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
3	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071â€22072 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	7.0	25
4	The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114082.	13.7	14
5	Mitochondrial DNA sequence variation and risk of glioma. <i>Mitochondrion</i> , 2022, 63, 32-36.	3.4	2
6	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab186.	0.7	1
7	High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors. <i>Journal of Neuro-Oncology</i> , 2022, 158, 33-40.	2.9	0
8	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. <i>Cancer Research</i> , 2021, 81, 2220-2233.	0.9	19
9	Digital measurement of functional status of patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2016-2016.	1.6	0
10	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populationsâ€An Exemplar in Brain Tumors. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 985-994.	2.1	2
11	Mitochondrial DNA sequence variation and risk of meningioma. <i>Journal of Neuro-Oncology</i> , 2021, 155, 319-324.	2.9	1
12	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020, 146, 739-748.	5.1	23
13	An Update on Neurofibromatosis Type 1-Associated Gliomas. <i>Cancers</i> , 2020, 12, 114.	3.7	50
14	ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity. <i>Cancers</i> , 2020, 12, 3069.	3.7	17
15	Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. <i>Nature Communications</i> , 2020, 11, 4660.	12.8	80
16	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. <i>Neuro-Oncology</i> , 2020, 22, 1713-1714.	1.2	0
17	Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortiumâ€™s first workshop on CNS drug delivery. <i>Neuro-Oncology</i> , 2020, 22, 1422-1424.	1.2	22
18	A troublesome burden, the amplification of EGFR in glioblastoma!. <i>Neuro-Oncology</i> , 2020, 22, 594-595.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1586-1594.	7.0	103
20	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	1.2	23
21	Abstract 3335: Characterization and analysis of the complement immune system in glioblastoma (GBM). , 2020, , .		0
22	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 73-79.	7.0	12
23	Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma. <i>Scientific Reports</i> , 2019, 9, 10861.	3.3	9
24	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	1.2	49
25	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
26	Highlights of the inaugural ten “the launch of Neuro-Oncology Advances. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz016.	0.7	0
27	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	1.1	20
28	Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. <i>PLoS Medicine</i> , 2019, 16, e1002810.	8.4	13
29	Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. <i>Cancer Biology and Therapy</i> , 2019, 20, 979-988.	3.4	43
30	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
31	An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. <i>CNS Oncology</i> , 2019, 8, CNS30.	3.0	9
32	MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	7.0	94
33	Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2017-2017.	1.6	10
34	Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2027-2027.	1.6	14
35	Management of Central Nervous System Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 579-582.	4.9	2
36	Abstract 2262: Chemotherapy, checkpoint inhibition, and MGMT-modified adoptive gamma-delta (γδ) T cell-based therapy to treat post-resection, primary glioblastomas. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
37	Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?. Journal of Neuro-Oncology, 2018, 138, 163-171.	2.9	28
38	Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. Cancer Research, 2018, 78, 3002-3013.	0.9	122
39	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi5-vi5.	1.2	0
40	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. Neuro-Oncology, 2018, 20, vi15-vi15.	1.2	1
41	NIMG-13. SEGMENTATION AND VOLUMETRIC ANALYSIS IMPROVES DETECTION OF PROGRESSION IN LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi178-vi178.	1.2	0
42	ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi14-vi14.	1.2	3
43	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi13-vi14.	1.2	6
44	ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 " FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS. Neuro-Oncology, 2018, 20, vi15-vi15.	1.2	0
45	Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment. Journal of Cancer Science & Therapy, 2018, 10, 190-197.	1.7	19
46	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. European Journal of Cancer, 2018, 101, 95-104.	2.8	11
47	Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. Journal of Clinical Oncology, 2018, 36, 2058-2058.	1.6	11
48	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2003-2003.	1.6	1
49	Abstract 233: Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos. , 2018, , .		0
50	When less is better: care of the elderly with glioblastoma. Neuro-Oncology, 2017, 19, 879-879.	1.2	0
51	Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-Oncology, 2017, 19, 845-852.	1.2	39
52	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	1.2	107
53	Older age at the completion of linear growth is associated with an increased risk of adult glioma. Cancer Causes and Control, 2017, 28, 709-716.	1.8	4
54	The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. Neurocase, 2017, 23, 287-291.	0.6	20

#	ARTICLE	IF	CITATIONS
55	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	2.3	108
56	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
57	Hu antigen R (HuR) multimerization contributes to glioma disease progression. <i>Journal of Biological Chemistry</i> , 2017, 292, 16999-17010.	3.4	43
58	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160
59	Repeatability of <sup>18</sup> F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 393-398.	5.0	27
60	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2003-2003.	1.6	9
61	Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2005-2005.	1.6	2
62	Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2021-2021.	1.6	1
63	Individualized screening trial of innovative glioblastoma therapy (INSIGHt).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2079-TPS2079.	1.6	14
64	Implementation and utilization of the molecular tumor board to guide precision medicine. <i>Oncotarget</i> , 2017, 8, 57845-57854.	1.8	67
65	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. <i>Oncotarget</i> , 2016, 7, 15018-15032.	1.8	62
66	Complications from pharmacotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 235-250.	1.8	4
67	Reply to F. Felix et al and M.F. Fay et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3107-3108.	1.6	2
68	Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma. <i>International Journal of Surgical Pathology</i> , 2016, 24, 753-756.	0.8	6
69	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. <i>Human Gene Therapy Clinical Development</i> , 2016, 27, 69-78.	3.1	113
70	Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme. <i>Nutrition and Cancer</i> , 2016, 68, 926-934.	2.0	1
71	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 731-739.	1.6	159
72	Analgesic use and the risk of primary adult brain tumor. <i>European Journal of Epidemiology</i> , 2016, 31, 917-925.	5.7	9

#	ARTICLE	IF	CITATIONS
73	Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2055-2055.	1.6	3
74	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2016, 34, 2542-2542.	1.6	5
75	Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases. Journal of the International Neuropsychological Society, 2015, 21, 412-418.	1.8	11
76	Capacity of patients with brain metastases to make treatment decisions. Psycho-Oncology, 2015, 24, 1448-1455.	2.3	24
77	SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Science Translational Medicine, 2015, 7, 289ra86.	12.4	207
78	Sellar Sarcoma Arising in Association With a Pituitary Adenoma. American Journal of Clinical Pathology, 2015, 144, A011-A011.	0.7	0
79	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v109.1-v109.	1.2	20
80	Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor. Neuro-Oncology Practice, 2015, 2, 13-19.	1.6	23
81	Ipilimumab-Induced Encephalopathy with a Reversible Splenic Lesion. Cancer Immunology Research, 2015, 3, 598-601.	3.4	57
82	Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas. Journal of Neuro-Oncology, 2015, 122, 585-593.	2.9	12
83	Growth Factor Dependent Regulation of Centrosome Function and Genomic Instability by HuR. Biomolecules, 2015, 5, 263-281.	4.0	14
84	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology, 2015, 17, 708-717.	1.2	191
85	Complementary therapy and survival in glioblastoma. Neuro-Oncology Practice, 2015, 2, 122-126.	1.6	25
86	Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. Journal of Clinical Oncology, 2015, 33, 3186-3192.	1.6	13
87	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. Journal of Neuro-Oncology, 2015, 125, 123-131.	2.9	8
88	Brain tumor risk according to germ-line variation in the MLLT10 locus. European Journal of Human Genetics, 2015, 23, 132-134.	2.8	22
89	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2009-2009.	1.6	56
90	Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study.. Journal of Clinical Oncology, 2015, 33, 2033-2033.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Abstract CT314: Interim results from a phase I/II trial of TPI 287, a novel brain penetrable antimicrotubule agent, in combination with bevacizumab for the treatment of recurrent glioblastoma. <i>Cancer Research</i> , 2015, 75, CT314-CT314.	0.9	1
92	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. <i>Molecular Therapy</i> , 2014, 22, 1048-1055.	8.2	233
93	Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. <i>Neuro-Oncology Practice</i> , 2014, 1, 172-177.	1.6	13
94	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2014, 17, 430-9.	1.2	108
95	Cognition in patients with newly diagnosed brain metastasis: profiles and implications. <i>Journal of Neuro-Oncology</i> , 2014, 120, 179-185.	2.9	51
96	Circadian pathway genes in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2014, 25, 25-32.	1.8	57
97	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	10.7	800
98	Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. <i>Journal of Neuro-Oncology</i> , 2014, 120, 361-370.	2.9	18
99	Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. <i>Journal of Neuro-Oncology</i> , 2014, 118, 61-72.	2.9	82
100	Reproductive factors and risk of primary brain tumors in women. <i>Journal of Neuro-Oncology</i> , 2014, 118, 297-304.	2.9	47
101	The Role of Bevacizumab in Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1201-1202.	4.9	2
102	The role of Src family kinases in growth and migration of glioma stem cells. <i>International Journal of Oncology</i> , 2014, 45, 302-310.	3.3	49
103	Role of MRI in Primary Brain Tumor Evaluation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1561-1568.	4.9	20
104	Early life exposures and the risk of adult glioma. <i>European Journal of Epidemiology</i> , 2013, 28, 753-758.	5.7	12
105	Toenail iron, genetic determinants of iron status, and the risk of glioma. <i>Cancer Causes and Control</i> , 2013, 24, 2051-2058.	1.8	8
106	SWI/SNF gene variants and glioma risk and outcome. <i>Cancer Epidemiology</i> , 2013, 37, 162-165.	1.9	12
107	Anthropometric factors in relation to risk of glioma. <i>Cancer Causes and Control</i> , 2013, 24, 1025-1031.	1.8	38
108	Mutant tristetrapirolin: a potent inhibitor of malignant glioma cell growth. <i>Journal of Neuro-Oncology</i> , 2013, 113, 195-205.	2.9	23

#	ARTICLE	IF	CITATIONS
109	Prediagnostic body weight and survival in high grade glioma. <i>Journal of Neuro-Oncology</i> , 2013, 114, 79-84.	2.9	30
110	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013, 15, 490-496.	1.2	79
111	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3212-3218.	1.6	489
112	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 900-908.	7.0	112
113	Rare TP53 genetic variant associated with glioma risk and outcome. <i>Journal of Medical Genetics</i> , 2012, 49, 420-421.	3.2	42
114	SSBP2 Variants Are Associated with Survival in Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3154-3162.	7.0	23
115	Phosphoregulation of the RNA-binding Protein Hu Antigen R (HuR) by Cdk5 Affects Centrosome Function. <i>Journal of Biological Chemistry</i> , 2012, 287, 32277-32287.	3.4	45
116	An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2012, 23, 1443-1449.	1.8	38
117	Primary central nervous system angiosarcoma: two case reports. <i>Journal of Medical Case Reports</i> , 2012, 6, 251.	0.8	18
118	A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). <i>Cancer</i> , 2012, 118, 5601-5607.	4.1	112
119	Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuR. <i>Journal of Neuroimmunology</i> , 2012, 246, 34-37.	2.3	12
120	Cilengitide: an RGD pentapeptide $\alpha$ 2 $\beta$ 3 and $\alpha$ 2 $\beta$ 5 integrin inhibitor in development for glioblastoma and other malignancies. <i>Future Oncology</i> , 2011, 7, 339-354.	2.4	98
121	Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011, 55, 77-81.	1.8	80
122	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. <i>Neuro-Oncology</i> , 2011, 13, 1324-1330.	1.2	39
123	Cancer susceptibility variants and the risk of adult glioma in a US case-control study. <i>Journal of Neuro-Oncology</i> , 2011, 104, 535-542.	2.9	77
124	Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 105, 375-381.	2.9	18
125	A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 639-646.	2.9	66
126	The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance. <i>Molecular Cancer Research</i> , 2011, 9, 648-659.	3.4	132



#	ARTICLE	IF	CITATIONS
127	Abstract 877: Genetic variation in podoplanin in relation to glioma risk and outcome. , 2011, , .		0
128	A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma. Archives of Neurology, 2010, 67, 313-9.	4.5	53
129	Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. Journal of Neuro-Oncology, 2010, 100, 95-103.	2.9	73
130	Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. Pediatric Blood and Cancer, 2010, 55, 1227-1230.	1.5	16
131	Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States. Clinical Cancer Research, 2010, 16, 2443-2449.	7.0	392
132	Capacity to Consent to Research Participation in Adults With Malignant Glioma. Journal of Clinical Oncology, 2010, 28, 3844-3850.	1.6	35
133	Rationally Designed Pharmacogenomic Treatment Using Concurrent Capecitabine and Radiotherapy for Glioblastoma; Gene Expression Profiles Associated with Outcome. Clinical Cancer Research, 2010, 16, 2890-2898.	7.0	29
134	Amyotrophic Lateral Sclerosis-linked Mutant SOD1 Sequesters Hu Antigen R (HuR) and TIA-1-related Protein (TIAR). Journal of Biological Chemistry, 2009, 284, 33989-33998.	3.4	55
135	Medical decision-making capacity in patients with malignant glioma. Neurology, 2009, 73, 2086-2092.	1.1	101
136	Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. Molecular Therapy, 2009, 17, 199-207.	8.2	346
137	Characterization and immunotherapeutic potential of $\hat{I}^{37}$ T-cells in patients with glioblastoma. Neuro-Oncology, 2009, 11, 357-367.	1.2	69
138	Isolated Central Nervous System Posttransplant Lymphoproliferative Disorder Treated with High-Dose Intravenous Methotrexate. American Journal of Transplantation, 2009, 9, 1243-1248.	4.7	36
139	High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magnetic Resonance in Medicine, 2009, 61, 615-625.	3.0	45
140	Distress and quality of life in primary high-grade brain tumor patients. Supportive Care in Cancer, 2009, 17, 793-799.	2.2	71
141	Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression. Clinical Cancer Research, 2008, 14, 4694-4704.	7.0	163
142	The ING4 Tumor Suppressor Attenuates NF- $\hat{I}^B$ Activity at the Promoters of Target Genes. Molecular and Cellular Biology, 2008, 28, 6632-6645.	2.3	100
143	Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-Oncology, 2008, 10, 608-616.	1.2	32
144	Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. Journal of Clinical Oncology, 2008, 26, 5610-5617.	1.6	448

#	ARTICLE	IF	CITATIONS
145	Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1225-1235.	4.1	174
146	Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1651-1657.	1.6	276
147	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1192-1199.	0.8	88
148	A novel technique to quantify glioma tumor invasion using serial microscopy sections. <i>Journal of Neuroscience Methods</i> , 2006, 153, 183-189.	2.5	4
149	1p/19q chromosome deletions in metastatic oligodendroglioma. <i>Journal of Neuro-Oncology</i> , 2006, 80, 203-207.	2.9	25
150	Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM). <i>Journal of Neuro-Oncology</i> , 2006, 80, 261-274.	2.9	51
151	Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3644-3650.	1.6	194
152	IL-1 $\beta$ induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. <i>International Journal of Cancer</i> , 2005, 113, 911-919.	5.1	93
153	Lyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor Cells. <i>Cancer Research</i> , 2005, 65, 5535-5543.	0.9	97
154	Treatment of adults with recurrent malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 509-514.	2.8	15
155	The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. <i>Nucleic Acids Research</i> , 2005, 33, 2962-2979.	14.5	104
156	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. <i>Molecular Therapy</i> , 2004, 10, 958-966.	8.2	401
157	Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate. <i>Clinical Cancer Research</i> , 2004, 10, 5643-5646.	7.0	196
158	Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. <i>Neuro-Oncology</i> , 2004, 6, 21-27.	1.2	98
159	Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 913-922.	3.4	80
160	Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. <i>Cancer Research</i> , 2003, 63, 4181-7.	0.9	105
161	Human cytomegalovirus infection and expression in human malignant glioma. <i>Cancer Research</i> , 2002, 62, 3347-50.	0.9	518
162	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 1139-45.	4.1	29

#	ARTICLE	IF	CITATIONS
163	Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. <i>Journal of Clinical Investigation</i> , 2001, 108, 1657-1665.	8.2	386
164	Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. <i>Journal of Clinical Investigation</i> , 2001, 108, 1657-1665.	8.2	72
165	Analysis of the 5' end of the mouse <i>Elavl1</i> (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organization. <i>Gene</i> , 2000, 242, 125-131.	2.2	17
166	Hu Antigen Specificities of ANNA-I Autoantibodies in Paraneoplastic Neurological Disease. <i>Journal of Autoimmunity</i> , 1999, 13, 435-443.	6.5	65
167	HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissues. <i>Journal of Neuroimmunology</i> , 1998, 92, 152-159.	2.3	37
168	Magnetic Resonance Cisternography in the Diagnosis of Delayed Iatrogenic Cerebrospinal Fistula: A Case Report. <i>Journal of Neuroimaging</i> , 1997, 7, 244-247.	2.0	2
169	Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis. <i>Journal of Neuroscience Methods</i> , 1988, 26, 1-23.	2.5	111
170	Quantitative immunocytochemistry using an image analyzer. II. Concentration standards for transmitter immunocytochemistry. <i>Journal of Neuroscience Methods</i> , 1988, 26, 25-34.	2.5	43
171	Catheter placement selection for convection-enhanced delivery of therapeutic agents to brain tumors. <i>F1000Research</i> , 0, 9, 1415.	1.6	3